Pathology and Therapeutics of COVID-19: A Review by Anwar, Haleema & Khan, Qudsia Umaira
International Journal of Medical Students – Review. 
1 
IJMS 
Title: Pathology and Therapeutics of COVID-19: A Review 1 
 2 
Author names: Haleema Anwar,1 Qudsia Umaira Khan.1 3 
Degrees: Haleema Anwar- Medical student; Dr. Qudsia Umaira Khan- MBBS, M.Phil., FCPS II 4 
Affiliations: 1.CMH Lahore Medical College & IOL, Lahore, Pakistan 5 
About the author: Haleema Anwar is currently a 2nd year medical student of MBBS at CMH Lahore Medical 6 
and Dental College, Lahore, Pakistan of a 5-years medical program. She is enthusiastically involved in medical 7 
research to keep herself abreast with the current techniques and technologies being used in the field of 8 
medicine. She is very energetic in social work, presently selected as a Head of a team in a blood donating 9 
society of the college 'Cmh LMC lifeline’. 10 
Acknowledgment: None 11 
Financing:  None 12 
Conflict of interest statement by authors: Dr. has nothing to disclose. 13 
Authors Contribution Statement: Writing – Original Draft: Miss.  Writing – Review & Editing: Miss, and Dr.  14 
Visualization: Miss.  Supervision: Dr.   15 
 16 
Manuscript word count: 3941 17 
Abstract word count: 150 18 
Number of Figures: 4 19 
Number of Tables: 3  20 
 21 
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1. General information: Where did the COVID-19 outbreak begin? Is it the only outbreak experienced by 23 
the world? When was it declared a Public Health Emergency of International Concern? What are the 24 
case fatality rate and Ro value for SARS-CoV-2? 25 
2. Virology: What is the structure of this new virus (genome and the protein expression)? How is the new 26 
virus related to other viruses (a phylogenetic analysis)? What are the receptors for the coronavirus?  27 
3. Diagnostics and pathophysiology: What are the various diagnostic methods available for the detection 28 
of COVID-19? What is the laboratory feature of patients with different severity of the viral infection? 29 
 How is it affecting the lungs, liver, heart and the nervous system? What is its case fatality rate by 30 
comorbidity (a graphical presentation)? What is the differential diagnosis of COVID-19? 31 
4. Therapy recommendation: What are the various drugs used to combat this infection so far? A brief 32 
tabulation of these drugs along with their type, property and mechanism of action. What platforms are 33 
being used for the development of vaccines against the infection? What recommendations are given by 34 
WHO and other organizations? 35 
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ABSTRACT. 1 
COVID-19 pandemic has taken over the world. Spreading from its epicenter in a seafood market in Wuhan, 2 
China to more than 200 countries, it has caused alarming situations. The viral infection is caused by an RNA 3 
virus called SARS-CoV-2. Its genome resembles the SARS-CoV-1 and MERS-CoV genome. COVID-19cases 4 
were first reported in December 2019 in China; it affects the lungs causing a mild to severe respiratory disease. 5 
No antiviral drug for the infection has been showed enough evidence, however many drugs are approved in the 6 
context of clinical trial. The review article will first present the structure of the SARS-CoV-2 and compare it to 7 
SARS-CoV-1 and MERS-CoV. The article will then highlight its effect on different organs. Finally, it will highlight 8 
the therapeutics which are in consideration and which are being used. Information was extracted from PubMed 9 
and Google Scholar. The article will provide a good insight into the COVID-19infection. 10 
 11 
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INTRODUCTION 1 
In December 2019, several cases of unexplained pneumonia appeared in Wuhan, China. The symptoms were 2 
like those caused by SARS-CoV (Severe Acute Respiratory Syndrome-Coronavirus) in 2003 which included 3 
cough, fever and fatigue. The infectious virus responsible for this was identified as SARS-CoV-2 and the 4 
infection was called COVID-19. Starting from its epicenter in China he COVID-19 has affected more than 200 5 
countries. The virus mostly causes mild cases. The status of COVID-19 for the world is: total deaths 310,003, 6 
total people recovered 1,780,118, and total cases 4,670,224 as on 16th May 2020, 4:00 pm GMT.40 7 
 8 
COVID-19 was declared a ‘global pandemic’ on March 11, 2020 by the director general of the World Health 9 
Organization (WHO).41 This study aims to present the structure of the SARS-CoV-2 and compare it to SARS-10 
CoV-1 and MERS-CoV, highlight its effect on different organs, and the therapeutics which are in consideration 11 
and which are being used. Information was extracted from PubMed and Google Scholar using keywords as: 12 
“COVID-19”, “SARS-CoV-2”, and “Pandemic”. 13 
 14 
Previous pandemics 15 
The COVID-19 is not the only pandemic that has been experienced by the world. Coronavirus has caused 16 
infections outbreaks previously. These include SARS-CoV and MERS-CoV (Middle East respiratory 17 
syndrome-coronavirus). SARS-CoV was identified in 2003. It began in China causing approximately 8000 18 
cases. MERS-CoV began in KSA (Saudi Arabia) in 2012. It led to 2500 cases.1 Each virus caused 800 19 
fatalities. 20 
 21 
Measure of the infectiousness of the disease is of significance. It is depicted by a value called Ro. Ro is the 22 
number of secondary cases per case in a totally susceptible population. At present the value has been 23 
calculated to be 2.68 for COVID-19 worldwide. Ro greater than 1 means that the case number increases. A 24 
comparison of  maximum and minimum Ro for SARS-CoV-2 with other coronaviruses is shown in Figure 1. 25 
This value might change at the end of the pandemic. The figure elucidates that the highest infectiousness was 26 
for SARS-CoV-2. The seriousness and severity of the disease is measured by case fatality. At present the 27 
case fatality of COVID-19 is 2% (i.e. 1 in 50 people with the disease die). For MERS-CoV it was 37% and for 28 
SARS-CoV it was 10%. 2 There may be discrepancies in the data because most of the COVID-19 patients are 29 
asymptomatic and therefore many patients have not been tested.  30 
 31 
Structure of SARS-CoV-2 32 
SARS-CoV-2 is the name given to the causative agent of COVID-19infection by International Virus 33 
Classification Commission, a member of the coronavirus family. Coronaviruses have four known genera. 34 
Alphacoronavirus, Betacoronavirus, Gammacoronavirus, Deltacoronavirus. Seven CoVs have been identified 35 
so far that may infect humans (HCoVs): two of which are alphacoronavirus (229E and NL63) and the other are 36 
Betacoronavirus (such as OC43, HKU1, SARS-CoV-2).4 SARS-CoV-2 has been classified as β-CoV. Corona 37 
is a Latin word which means crown, it is named so because the surface projection on a viral envelope gives it 38 
such an appearance. 39 
 40 
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CoVs are RNA enveloped viruses with nucleocapsid. It has a genome of around 30 kb in length, which makes 1 
it the largest known RNA viruses, and diameter of approximately 60–140 nm. The SARS-CoV-2 has ten ORFs 2 
(Open Reading Frames).5  3 
 4 
The genomic structure had 5′-cap structure and 3′-poly-A tail and encodes for structural and non-structural 5 
proteins. The structure has mainly four structural proteins: spike (a glycoproteins composed of two subunits 6 
S1 and S2) which helps the virus to attach to the host, membrane which help shape the virion particle, 7 
envelop which is involved in assembly and release of particle, and nucleocapsid which aids the binding of 8 
genome to replication transcription complex for the replication of its genetic material.4  9 
 10 
Phylogenetic analysis revealed that COVID-19is 80% and 50% identical to SARS-CoV and MERS-CoV, 11 
respectively. As shown in Figure 2. Both viruses were bat in origin. A single intact open reading frame was 12 
found on gene 8. All these evidences point out that the possible origin of COVID-19virus is from bat. 13 
 14 
MERS-CoV uses dipeptidyl peptidase (DPP4) as a receptor whereas SARS-CoV and SARS-CoV-2 utilize 15 
ACE-2 (Angiotensin-Converting Enzyme-2) as their receptors, which is a membrane bound aminopeptidase. 16 
SARS-CoV-2 entry is dependent on protease. The most important being the employment of protease 17 
Transmembrane Serine Protease 2 (TMPRSS2) for priming of the viral S protein. This is of significance as 18 
TMPRSS2 activity is important for viral spread and pathogenesis.5  These receptors are under 19 
pharmacological considerations. 20 
 21 
The incubation period of COVID-19 is calculated to have a median of 6.4 days.15 This gives information about 22 
how long it takes for a patient infected with SARS-CoV-2 to develop symptoms and forms the basis for 23 
quarantine period. A longer incubation period signifies a higher rate of asymptomatic and subclinical infection 24 
in individuals who are immunologically competent. A comparison of three related viruses is shown in Figure 3, 25 
wherein we have chosen the maximum value of the period i.e. 2 – 7 duration of SARS-CoV-1, we selected 7. 26 
The virus is very infectious, and a study on familial group of five patients has revealed that asymptomatic 27 
carriers can transmit the infection to others even when the virus is in the incubation period.28 28 
Diagnosis and Pathology 29 
Various methods for the diagnosis of the infection are used. These include RT-qPCR (Real-Time quantitative 30 
Polymerase Chain Reaction), High-throughput sequencing, CT scan and immunological detection kits. These 31 
methods are shown in Table 1. 32 
 33 
After the onset of the infection, the clinical manifestation ranged from asymptomatic patients to patients with 34 
septic shock. As the disease progresses, it may be categorized  as mild, moderate, severe or critical. 81% of 35 
the cases were mild. Cases critical in severity were reported to be 5%.18 Case fatality rate of patient with a 36 
chronic illness and patient of critical severity was high. 37 
 38 
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Laboratory features for early stage ICU patients and critical patients were the following: CD4 and CD8 1 
lymphocytes were reduced in patients of early stage. Interleukin level (IL-2, IL-7, IL-10), granulocyte colony 2 
stimulating factor and tumor necrosis factor-α were high in intensive care unit patients. Amylase levels were 3 
high in critical patients. C-reactive protein (CRP) levels are directly proportional to disease severity and its 4 
progress.18 From pieces of evidence, it has been suggested that there is a subgroup of severe COVID 5 
patients that might have a complaint of cytokine storm syndrome. In this condition, there is an urgent need to 6 
reduce rising mortality by using approved, existing therapies and treatments of hyper inflammation with safety 7 
profiles and measures. The current method of managing and curing COVID-19 patients is supportive and 8 
protective. It has been investigated that the prime cause of death in COVID-19 patients is the respiratory 9 
failure that is due to Acute Respiratory Distress Syndrome (ARDS). Another syndrome that is characterized by 10 
sudden and severe fatal hypercytokinemia with the probability of multi-organ failure is Secondary 11 
Haemophagocytic Lymphohistiocytosis (sHLH). It is a hyperinflammatory syndrome that is generally triggered 12 
by viral infections in adults and responsible for 3.7–4.3% of sepsis cases. Major features of sHLH are fever, 13 
hyperferritinanemia, cytopenia, and involves pulmonary system (ARDS) in 50% cases.COVID-19 disease 14 
severity is analyzed by resembling cytokine profile with sHLH. It is characterized by an increased number of 15 
interleukins, monocytes, interferons, macrophages, inflammatory proteins, and TNF. The study of 150 COVID 16 
cases shows mortality from a recent retrospective.29,30  17 
 18 
SARS-CoV-2 stands for Severe Acute Respiratory Syndrome. It is found to damage the lungs, but its effects 19 
are not limited to the lung tissue. Its influence on liver, Central nervous system (CNS) and cardiovascular 20 
system (CVS) are under consideration. SARS-CoV-2 infects ciliated bronchial epithelial cells and type II 21 
pneumatocytes of lung tissue.6 In a study, biopsy samples were taken from the lung tissue. It showed 22 
desquamation of the pneumatocytes, hyaline membrane formation and pulmonary edema. All these findings 23 
are suggested of an acute respiratory distress syndrome (ARDS). In the intersitium, mononuclear 24 
inflammatory infiltrates were seen mainly dominated by the lymphocyte. The intra alveolar space showed viral 25 
cytoplasmic-like changes, which included multinuclear syncytial cell with atypically enlarge pneumatocytes 26 
that had prominent nucleoli, large nuclei and amphophilic granular cytoplasm.7 SARS-CoV, SARS-CoV-2 and 27 
MERS-CoV infect a cell in common which is the type II pneumatocytes. MERS-CoV differed from other in that 28 
it damaged the unciliated bronchial epithelial cells as compared the ciliated bronchial epithelial cell infected by 29 
SARS-CoV and SARS-CoV-2. 30 
 31 
SARS-CoV-2 can directly bind to ACE 2 receptors on cholangiocytes leading to problems with the biliary 32 
system and secondary causing injury to the liver. This finding was in congruence with a study in which patient 33 
in subclinical phase (that is before the onset of the symptoms) had lower Aspartate Aminotransferase (AST) 34 
level abnormality then the patients who were diagnosed after the onset of the symptoms.8 Inflammation 35 
caused by immunity (i.e. cytokine storm) can cause liver damage. Hypoxia due to respiratory syndrome 36 
causes lack of oxygen to the liver tissue contributing to liver dysfunction. In MERS-CoV, no viral particle was 37 
detected in liver tissue.14 The association of extreme severity of Corona or COVID-19 disease to a cytokine 38 
profile that resembles secondary haemophagocytic lymphohistiocytosis (sHLH). This is distinguished by 39 
increased IL (interleukin)-2, IL (interleukin)-7, G-CSF or GCSF (granulocyte colony-stimulating factor), IFN 40 
(interferon)-γ inducible protein 10, MCP (monocyte chemoattractant protein) 1, MIP (macrophage 41 
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inflammatory protein) 1-α, and TNF (tumour necrosis factor)-α.6. A multi-center study (clinical research of 1 
multi-labs and clinics) of 150 confirm COVID-19 cases predicted fatality from some recent retroactive study.  2 
Hyper-inflammatory screening should be done, with the help of recent clinical-lab inventions, for the patients 3 
who suffer severe Coronavirus infection. The clinical techniques to keep a check on ferritin increase, decrease 4 
in platelet count, or erythrocyte sedimentation rate. Along with the screening, HScore11 (patient's 5 
performance record table) to distinguish the patients who can show transience improvement through immuno-6 
suppression. Ingestion or intake of steroids, intravenous immunoglobulin, selective cytokine blockade, and 7 
JAK inhibition are some opt able curative options.31 8 
 9 
The functional receptor of SARS-CoV-2 is ACE 2. This receptor is present on different human tissue which 10 
include nervous tissue, skeletal muscle, cardiac tissue and liver tissue. In a study of 214 COVID-19 patients, it 11 
was revealed that these patients had neurological symptoms of PNS and CNS.9 The symptoms were more 12 
pronounced in patients with severe infection of COVID-19. The symptoms were acute cerebrovascular 13 
disease and conscious disturbance. CNS symptoms included dizziness and headache. In comparison to other 14 
coronaviruses, neurological injury was confirmed in SARS-CoV and MERS-CoV. SARS-CoV nucleic acid was 15 
detected in CSF and brain tissue biopsy of the patients. A case study supports the possibility of the COVID-19 16 
causing neurological dysfunctions. A COVID-19 infected 61-year-old women presented with acute weakness 17 
and severe fatigue of lower limbs. There was a decrease in sensation of light touch and pinprick. Laboratory 18 
findings revealed demyelinating neuropathy. She was diagnosed Guillain-Barré syndrome.  This might 19 
suggest an association between SARS-COV-2  and the syndrome because the starting point of the syndrome 20 
overlapped the duration of COVID-19 infection.9 21 
 22 
ACE 2 is highly expressed in lung and heart tissue.10 SARS-COV-2 enters the lung tissue via type II 23 
pneumatocytes. This viral entry causes down-regulation of ACE-2 receptor which leads to accumulation of 24 
Ang II (angiotensin II) and reduced angiotensin-(1–7). Ang II-induced cardiac hypertrophy, fibrosis and 25 
infarction are the consequences of increased level of circulating Ang II.11Acute myocarditis and heart failure 26 
can be caused by MERS-CoV. There is some mechanism by which heart injury is caused which includes 27 
hypoxemia complications, ACE 2 related signaling pathways and an unbalanced response of two helper cells 28 
(Type 1 and Type 2) leading to cytokine storm.2 Figure 4 shows COVID-19 fatality rate by comorbidity. 29 
 30 
In patients who had COVID-19and sepsis various signs and symptoms were observed. Severe dyspnea and 31 
hypoxemia due to the damage to lungs, renal impairment and decreased urine output because of kidney 32 
damage, and tachycardia.1 There are certain cardiovascular complications due to viral infections that include 33 
myocarditis, heart failure, myocardial infarction of type 1 and 2, arrhythmias, pericarditis, and myocardial 34 
ischemia. The covid-19 is impacting many populations in the world. According to the current published data, 35 
many patients who are suffering from Covid-19 develop some cardiovascular complications. Almost 7% 36 
develop acute cardiac injuries, while 16% of the patients develop arrhythmia. Heart failure is caused in 23 % 37 
of the COVID-19 patients. The reasons for heart failure are stress cardiomyopathy, new cardiomyopathy, and 38 
myocarditis. The new cardiomyopathy is to the strong cytokine storm.  Procoagulant activity, as well as 39 
systematic inflammatory response along with Covid-19, can increase the risk of acute myocardial infarction 40 
and cardiac injury. There may be a chance of myopericarditis, but it's rare. Some complications are 41 
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associated with women only e.g. stress and cardiomyopathy. These are preceded by physical triggers or 1 
emotional triggers. Stress cardiomyopathy is usually associated with left ventricular function as compared to 2 
the coronary syndrome.35,36    3 
 4 
 5 
In a cohort study of 41 patient confirmed with the infection were admitted to hospital in Wuhan China. Certain 6 
features of the infection were like SARS-CoV and MERS-CoV which were fever, dry cough and dyspnea.2 7 
Other similarities included: pneumonia, nonproductive cough, myalgia and fatigue.4 However, COVID-8 
19differed in that it showed apparent signs and symptoms of upper respiratory tract (e.g., rhinorrhea, sneezing 9 
or sore throat) and did not show intestinal signs and symptoms. MERS-CoV induced increased concentration 10 
of proinflammatory cytokines (IFNγ, TNFα, IL15, and IL17).25 Patient infected with COVID-19 also had high 11 
amounts of IL1B, IFNγ, IP10, and MCP1. COVID-19 differed from SARS-CoV as COVID-19 caused an 12 
increase in secretion of T-helper-2 cytokines (e.g. IL4 and IL10).2 13 
 14 
There are some complications due to COVID-19 that must be brought into light. These are ARDS, Cytokine 15 
storm complicated with hemophagocytic syndrome, Myocardial injury and Coagulopathy. There is a high risk 16 
of venous thromboembolism. D‐dimer might be helpful in early recognition of patients with high risk of such 17 
coagulations.32 In a study of 449 patients with severe COVID‐19 who had sepsis‐induced coagulopathy 18 
criteria or elevated levels of D‐dimer, anticoagulant therapy was given and the result showed a lowered 19 
mortality. They were treated with low molecular weight heparin (LMWH).37 20 
 21 
Differential diagnosis is very important to give appropriate and timely treatment to the patient. It includes the 22 
possibility of an infectious or non-infectious respiratory disease.1 These disorders include common cold 23 
caused by Rhinovirus, upper and lower respiratory disease by Human Metapneumovirus (hMPV) and 24 
pneumonia caused by influenza and parainfluenza. Investigations such as detection of antigen must be 25 
carried out to eradicate the possibility of such diseases. 26 
 27 
Therapeutics 28 
There is no antiviral treatment that has been approved for COVID-19, however, certain approaches for the 29 
cure are under consideration. 30 
 31 
The base-line treatment for the patient infected with SARS-CoV-2 is symptomatic. Isolation of the individual is 32 
most effective and oxygen therapy is recommended. The measure taken to contain the epidemic is quarantine 33 
because the virus is transmitted by human to human contact and physical contact with surfaces (i.e. 34 
cardboard, copper, stainless steel, plastic). Zoonotic transmission has also been stated. Drug intervention 35 
includes antiviral, antibacterial and antimalarial drugs.  36 
 37 
As the virus affects the lungs, the major therapy for the infection is oxygen therapy. One of the preferred 38 
strategies is the endotracheal tube. It is recommended in patients with critical respiratory conditions. A 39 
waveform capnograph monitoring device should be used. This gives information about correct placement of 40 
endotracheal tubes and gives an idea about the extent of seal adequacy. High-flow nasal oxygen (HFNO) or 41 
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non-invasive ventilation (NIV) improve oxygenation and lower the work of breathing but are not recommended 1 
for the treatment as they produce aerosol and the virus can be aerosolized. Their use is discouraged 2 
universally unless an airborne infection isolation room is accessible, or the patient has viral clearance.12 3 
 4 
Study reveals that chloroquine has antiviral activity against RNA viruses in vitro. Several mechanisms by 5 
which this drug works is proposed. It might be due to interference of chloroquine with ACE 2 receptor 6 
glycosylation which prevents its attachment to the host cell. Chloroquine can work indirectly by reducing pro-7 
inflammatory cytokines. Preliminary study indicated that the drug interferes with SARS-CoV-2 attempt to 8 
acidify lysosome, thus it works by increasing endosomal pH.17 9 
 10 
Remdesivir is an antiviral prodrug. It has been tested in animal model (i.e. mice), the test revealed that the 11 
drug reduced viral load in SARS-CoV infected mice. Remdesivir was used in three patients with severe 12 
disease. In one patient it was discontinued after 5 days because of ALT elevation. There was no confirmation 13 
whether this elevation was due to Remdesivir. A patient of renal replacement therapy was given only one 14 
dose and then Remdesivir was discontinued because it contained cyclodextrin (which has a clearance related 15 
to creatinine linearly).13 According to a placebo-controlled, multicenter trial for Remdesivir in ten hospitals in 16 
China, the drug did not show significant reduction in mortality or time to clearance of virus in seriously ill 17 
patients as compared with placebo group. A numerical reduction in time of recovery was observed in patients 18 
who were treated earlier.34 Although there is inadequate knowledge about the safety and effectiveness of 19 
Remdesivir, the drug has shown to shorten the time of recovery in some COVID-19 patients. It has been 20 
authorized for emergency use by FDA. 21 
 22 
Many biopharmaceutical companies are aiming to develop prophylactic vaccines for the virus. These attempts 23 
are being made using DNA, mRNA and adenovirus vectors as platforms. Due to technological improvement, 24 
mRNA vaccines are more stable and have high efficiency for protein translation. These properties induce a 25 
strong immune response. The most advanced platform is DNA. mRNA is a disruptive vaccine technology.16 26 
Table 2 shows a list of recommended drugs for the COVID-19.   27 
 28 
An expert consensus recommended chloroquine phosphate tablets (500 mg twice per day for 10 days) for 29 
mild to severely infected patients.17 Certain precautions were also highlighted. These were blood testing, 30 
routine electrocardiography, administration of antiarrhythmic, antidepressant and antipsychotic drugs. Their 31 
precautions were recommended to exclude the possibility of anemia, thrombocytopenia or leukopenia, 32 
electrolyte disturbances, QT interval prolongation or bradycardia. 33 
 34 
Dutch Center of Disease control suggested the need to stop treatment with Chloroquine (CQ) at day five as 35 
the drug has a long half-life and can cause side effects. It also highlighted the need to differentiate between 36 
regimens based on chloroquine phosphate and chloroquine base. Italian scientists recommended a dose for 37 
patients with mild to severe respiratory symptoms. The recommendation states the use of chloroquine or 38 
Hydroxychloroquine (HCQ).17 The use of CQ and HCQ is still controversial due to low clinical study at present. 39 
 40 
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CQ is largely being considered for the treatment for COVID-19. A study was carried out in Manaus, Brazilian 1 
Amazon to test the dosage of the drug. CQ was given orally or by nasogastric tube. High dose was given to 2 
one group (i.e. a total dose of 12g over a period of 10 days) and low dosage was given to another group ( i.e. 3 
a total dose of 2.7g for 5 days). The results were against the use of high dose because it raised safety 4 
concerns.18 5 
 6 
To determine the efficiency of HCQ study was conducted in Renim Hospital of Wuhan on 62 patients. The 7 
result showed a decrease in time to clinical recovery and cough remission time. Pneumonia absorption was 8 
also noted. This favors the use of HCQ under managed circumstances. A large-scale research is still required 9 
for absolute support for the use of HCQ at large scale.19 10 
 11 
Two lead compounds have been designed 11a and 11b. These lead compounds bind to Cys145 of Mpro (a 12 
protease used by the virus for entry into cells) via the aldehyde group. Trials were conducted in mice which 13 
revealed that 11b has shorter half-life and faster clearance than 11a. 11a showed lower toxicity. Thus, the 14 
pharmacokinetic (PK) properties indicate that these are good candidates for treatment of SARS-COV-2.21 As 15 
TMPRSS2 is use for viral entry, their inhibitor (such as camostat mesylate) can block the infection. Interferons 16 
inhibit replication of SARS-CoV in vitro. The effectiveness of interferon β, Interferon α and Interferon γ was 17 
studied. The result showed that interferon β was most potent amongst all of them. Thus, Interferon β could be 18 
a drug used for treating the SARS.22 19 
 20 
Some promising therapies are Remdesivir, vaccine, plasma therapy and stem-cell transfusion. Convalescent 21 
plasma has been used to treat previous outbreak like Ebola and MERS. This immunoglobulin treatment is 22 
understudy for COVID-19 because it blocks infection and suppresses viremia.23 23 
 24 
Trial for vaccine development are accelerating. The aim is to device a vaccine which will be suitable for 25 
stocking, suitable for adult health care workers and adults with underlining hypertension and diabetes. The 26 
major vaccines that have been established are whole virus vaccine, subunit vaccines and nucleic acid 27 
vaccine.24 28 
 29 
Various companies and universities around the globe are working to develop the vaccine for COVID-19. At 30 
present, more than 90 vaccines have been designed.26 The vaccine presents antigen to the body for immunity 31 
to combat the infection when a person is infected. The type of vaccines being used are virus vaccine, viral 32 
vector vaccine, nucleic acid vaccine and protein-based vaccine, as shown in Table 3. 33 
 34 
Convalescent plasma(CP) therapy is also being considered for the treatment because it has shown to 35 
decrease serum cytokine response. This is of great importance as viremia reaches its peak in the first week 36 
after infection and in the second week after onset of symptoms there is a cytokine storm which could prove to 37 
be life threatening.38 SARS-CoV-2 induces a cytokine storm in the patients and CP therapy might be the gate 38 
way to improve this condition. CP has its limitations as it causes adverse results like chills, fever, anaphylactic 39 
reactions, transfusion-related acute lung injury, circulatory overload and hemolysis.39 40 
 41 
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For the limitation of onward spread of the virus between individuals to contain the epidemic and slow its 1 
progression, WHO and other organizations have given some recommendation for the prevention of spread of 2 
the infection. These recommendations include staying away from subjects who have acute respiratory 3 
infections, washing hands habitually, covering coughs or sneezes. Public gathering must be avoided 4 
especially by subjects with a compromised immune system. 5 
 6 
 7 
 8 
DISCUSSION and CONCLUSION 9 
 10 
This article has led to the finding that coronavirus outbreaks have occurred before. This outbreak is unique 11 
due to the extent of emergency situations it has caused around the world. SARS-CoV- 2 dose hold certain 12 
similarities with MERS-CoV and SARS-CoV- 1 in terms of genetics, receptor (i.e. ACE-2 receptor used by 13 
SARS-CoV- 1 and SARS-CoV- 2) and some symptoms. Ro, case fatality and incubation periods are 14 
distinctive for SARS-CoV- 2.This information is of importance because it serves as a pioneer for the 15 
establishment of treatment. 16 
 17 
The study has limitations in terms of the time it has been done in because the pandemic has not been 18 
contained yet. Thus, some conclusions drawn from clinical trials and tests may change in future due to a 19 
better understanding on grounds of latest research. 20 
 21 
The pandemic has posed obstacles in many aspects including economic, environmental, and psychological. 22 
The most significant obstacle, at present, is its treatment because it is a certain tool to eradicate the COVID-23 
19 infection and subsequently all problems that are arising due to it will settle down (especially the issue of 24 
economic crisis). Studies support that the best treatment is quarantine. The absolute treatment for the 25 
infection will take time and a great deal of future research. 26 
 27 
The review has emphasized the virology, pathology and therapeutics of the most recent pandemic ‘COVID-28 
19’. The pandemic is still escalating. It is evident from the literature that the effect of this viral infection is not 29 
only bound to the lungs but is also harming other systems of the body. The exact mechanism about how 30 
COVID-19 is  associated with certain disorders (such as neurological and cardiac) still require further 31 
research. This explains the complexity of the disease itself and difficulty for the search for its cure. At this 32 
point of the pandemic, there are an appreciable number of drugs and other therapeutic methods that have 33 
been researched but the absolute treatment is still to be achieved. Continuous development and research are 34 
underway to form a promising medication. Especially work is being done to design a vaccine for the infection 35 
and the latest researches are pointing towards a promising result. 36 
37 
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Figure 2. Genetic Similarity of SARS-CoV-2 with other Viruses 1 
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Figure 3. Incubation periods of the viruses 1 
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Figure 4. COVID-19 Fatality Rate by Comorbidity 1 
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Table 1. The various diagnostic methods used for detection of COVID-19. 1 
Diagnostic method Efficiency and Limitations 
RT-qPCR (Real-Time quantitative 
Polymerase Chain Reaction) 
High sensitivity and specificity 
Limitation:  
 long waiting time for result 
 Can show false-negative result 
High-throughput sequencing Authoritative identification method 
Limitation: 
 High cost 
 Equipment dependency 
CT scan Has higher clinical diagnostic value for 
COVID-19 
Limitation:  
 cannot distinguish between pneumonia 
caused by COVID-19or another 
pathogen 
 Hysteresis of abnormal CT imaging  
Immunological detection kits  ELISA kits have been developed and 
pretested by some companies 
 SARS-CoV N-based Ig G ELISA has 
higher sensitivity than S- based Ig G 
ELISA. 
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Table 2. A list of recommended drugs with their properties and possible mechanism of action. 1 
 2 
  3 
  4 
Drug  Type Properties and mechanism of action 
Chloroquine Antimalarial  Pharmacokinetics:  
 Reaches maximum plasma level in 3 hours 
 Principally excreted by kidney with initial half-
life of 3-5 days and terminal half-life of 1-2 
months 
Mechanism: 
 Halts pH-dependent entry of virus by altering 
pH of endosome. Therefore, viral genome is 
not released in the cytosol because the viral 
and endosomal membrane fail to fuse. 
 It interferes with sialic acid biosynthesis. Sialic 
acid forms a complex with protein capsid of 
virus that interact with cell surface receptor of 
human cell 
Kaletra (Co-formulation of 
Lopinavir and ritonavir)  
 Antiviral Inhibitor of cytochrome P450 3A. 
Ivermectin Anti-parasitic  Single dose controls viral replication in 24-48 
hours 
 A hypnotised mechanism of action is by 
inhibition of nuclear import of viral protein by 
the drug. 
Remdesivir Antiviral  It inhibits viral RNA polymerase, thus prevents 
viral multiplication  
Teicoplanin  Antibiotic   Used for treatment of gram-positive bacteria 
 Inhibits cleavage of viral spike protein at low 
pH by Cathepsin L. 
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Table 3. 1 
VACCINE TYPE TRIALS 
Virus Vaccine 1.Weakened virus: Mutations are introduced in 
the virus by passing it through animal and 
human cells to decrease its infectiousness 
 
2.Inactivated virus: Chemicals or heat is used 
to make the virus infectious 
Codagenix in Farmingdale, 
New York, and Serum 
Institute of India are 
working in collaboration to 
weaken the virus by 
changing the genetic code. 
 
Sinovac Biotech in Beijing 
has started to test an 
inactivated version of 
SARS-CoV-2 in humans 
Viral vector 
Vaccine 
1.Replicating viral vector: A virus is 
genetically modified so that it does not cause 
disease. This type replicates in the cells. 
 
2.Non-replicating viral vector: These are also 
genetically engineered but do not replicate 
because the key gene has been disabled 
Around 25 groups are 
working on viral-vector 
vaccines. 
 
US-based drug giant 
Johnson & Johnson is 
working on Non-replicating 
viral vaccine 
Protein based 
Vaccine 
1.Protein subunits: Coronavirus proteins are 
directly injected into the body. This includes 
the use of the virus spike protein or other key 
part. 
2.Virus-like particles: These are empty virus 
without the genetic material and thus are not 
infectious. 
At present 28 teams are 
working on vaccines with 
viral protein subunits. 
5 teams are working on 
‘virus-like particle’ (VLP) 
vaccines. 
Nucleic acid 
vaccine 
1.DNA-based vaccine: Genetic code for 
coronavirus protein is injected in form of 
DNA.  
2.RNA-based vaccine: RNA is used as genetic 
instruction for coronavirus protein.  
Typically, the spike protein is encoded. 
20 teams are aiming to use 
this technique 
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